Lipum AB (publ) (STO:LIPUM)

Sweden flag Sweden · Delayed Price · Currency is SEK
16.60
+1.30 (8.50%)
At close: Feb 17, 2025
91.69%
Market Cap 364.85M
Revenue (ttm) 53.00K
Net Income (ttm) -39.24M
Shares Out 21.21M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,926
Average Volume 10,762
Open 15.90
Previous Close 15.30
Day's Range 15.90 - 17.90
52-Week Range 5.50 - 18.40
Beta 0.28
RSI 62.25
Earnings Date Feb 26, 2025

About Lipum AB

Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-sti... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol LIPUM
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.